Diabetes and weight loss drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists have widespread effects in the brain, with new research presented at the Society for Neuroscience’s Neuroscience 2024 uncovering potential novel therapeutic benefits and behavioural side effects.

About one in eight adults report having taken a GLP-1 receptor agonist – a class of medications that includes Ozempic, Wegovy, and Zepbound. Originally used to treat type 2 diabetes, these GLP-1-based drugs have recently become popular for their effects on reducing food intake and body weight.

Since GLP-1 receptors are widespread throughout the brain, it is likely that GLP-1 medications have additional, unknown effects on the brain and behaviour. Researchers are still learning about their potential uses for conditions beyond diabetes and obesity.

SfN new findings

The new findings presented at the event show that GLP-1 receptor agonists are effective in treating diabetes and obesity but may have other therapeutic benefits as well as behavioural side effects.

Emile Andriambeloson from Neurofit presented, ‘Semaglutide’s cognitive rescue: insights from rat and mouse models of Alzheimer’s disease’. This showed:

  • Mouse and rat models of Alzheimer’s disease showed improvements in memory dysfunction after treatment with semaglutide.
  • Semaglutide demonstrated anti-inflammatory properties in rat brain cells grown in laboratory dishes.
  • The findings suggest semaglutide may potentially be a new treatment option for Alzheimer’s disease by reducing brain inflammation and thereby improving cognitive deficits.

Yong Ho Kim from Gachon University presented, ‘GLP-1 and its derived peptides mediate pain relief through direct TRPV1 inhibition without affecting thermoregulation’. This showed:

  • GLP-1 and related peptides can directly engage and deactivate a key receptor involved in sensing pain called the transient receptor potential vanilloid 1 (TRPV1) channel.
  • The GLP-1 peptides alleviated both acute and chronic pain in mice without raising body temperature, which commonly occurs with other treatments that target the TRPV1 channel.
  • The results reveal a potential novel mechanism for pain management that may offer advantages over current pain medications.

Ralph DiLeone from Yale University presented, ‘Semaglutide administration reduces free running as well as motivation for wheel access as measured by progressive ration in mice’. This showed:

  • Typically, mice will voluntarily run on a wheel and will work for access to the wheel.
  • During treatment with semaglutide, mice reduced total wheel running time and the amount of work they were willing to perform to access a running wheel, while also reducing food intake.
  • The results suggest that GLP-1 drugs may affect multiple behaviours related to the brain’s reward systems, including reducing the motivation to exercise.

“With millions of patients currently taking these drugs, there is an urgent need to understand their effects on the entire brain,” said Dr Karolina Skiblicka, a Neuroscientist at Pennsylvania State University who studies gut-brain communication using rodent models. “These studies highlight how much there is still to discover even after decades of research on GLP-1.”

Megan Thomas, Multimedia Editor, DDW